医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AVITA Medical Announces Results of Extraordinary General Meeting

2018年07月24日 AM05:54
このエントリーをはてなブックマークに追加


 

VALENCIA, Calif. & MELBOURNE, Australia

AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications, announced that both resolutions presented to shareholders were approved at an Extraordinary General Meeting held today. The Extraordinary General Meeting of the Members of AVITA Medical Limited was held at 10:00 a.m. AEST today at the offices of K&L Gates, Melbourne, Australia. The results of the vote are summarized below.

Both resolutions related to the June 2018 institutional placement of shares to international and Australian institutional and sophisticated investors for A$16 million, with the placement occurring in two tranches. Tranche 1 of the institutional placement, totaling A$12.77 million, settled on 12 June 2018. Settlement of Tranche 2 totaling A$3.25 million was subject to shareholder approval at today’s Extraordinary General Meeting, and as a result of today’s vote will settle in late July 2018.

Resolution 1- Ratification of Prior Issue Shares

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 153,285,399 Shares to professional and sophisticated investors prior to the date of this meeting on the terms and conditions set out in the Explanatory Statement.”

Details of proxies received were as follows:

 
   

Number

   

%

Votes cast FOR the motion 133,737,890 91.09%
Votes cast AGAINST the motion 11,364,025 7.74%
Proxy’s discretion

1,717,295

1.17%

Total Votes Cast 146,819,210

100.00%

Votes Abstained 1,576,766
 

The resolution was passed unanimously on a show of hands.

Resolution 2- Approval to Issue Shares to Raise up to $3.25 Million

“That for the purposes of ASX Listing Rule 7.1 and for all other purposes, shareholders approve and authorise the Company to issue up to 65,000,000 ordinary shares at an issue price of $0.05 per share to professional and sophisticated investors raising in aggregate $3.25 million and otherwise on the terms detailed in the Explanatory Statement.”

Details of proxies received were as follows:

 
    Number     %
Votes cast FOR the motion 112,199,481 83.33%
Votes cast AGAINST the motion 20,473,666 15.21%
Proxy’s discretion 1,970,585 1.46%
Total Votes Cast 134,643,732 100.00%
Votes Abstained 13,752,244
 

The resolution was passed unanimously on a show of hands.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. Our medical devices work by preparing a REGENERATIVE EPITHELIAL SUSPENSION™, an autologous suspension comprised of the patient’s own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This autologous suspension is then sprayed onto the areas of the patient to be treated.

In the United States, the RECELL Device is an investigational device limited by federal law to investigational use. In September 2017, AVITA Medical submitted to the U.S. Food and Drug Administration (FDA) a PreMarket Approval (PMA) application for RECELL for the treatment of burn injuries.

In all countries outside of Europe, our portfolio is marketed under the RECELL Device brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. RECELL Device is TGA-registered in Australia, and CFDA-cleared in China.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. RECELL Device is designed for the treatment of burns and plastic reconstructive procedures; REGENERCELL™ Autologous Cell Harvesting Device has been formulated for chronic wounds including leg and foot ulcers; and RENOVACELL™ Autologous Cell Harvesting Device is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180723005746/en/

CONTACT

OUS Media
Monsoon Communications
Sarah Kemter
Phone:
+61 (0)3 9620 3333
Mobile: +61 (0)407 162 530
sarahk@monsoon.com.au
or
US
Media

Syneos Health Public Relations
David Polk
Phone:
+1 (310) 309 1029
Mobile: +1 (805) 428 5775
david.polk@syneoshealth.com
or
Investors:
Westwicke
Partners

Caroline Corner
Phone: +1 (415) 202-5678
caroline.corner@westwicke.com
or
AVITA
Medical Ltd

Dale A. Sander
Chief Financial Officer
Phone:
+1 (858) 663-6993
dsander@avitamedical.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Urban Drinking Water Challenge 2018 Announces Winners from USA, India and Bangladesh
  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险